DUBLIN, March 18, 2024 /PRNewswire/ -- The 'Global Neutropenia Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis' report has been added to ResearchAndMarkets.com's offering.

都柏林，2024年3月18日/PRNewswire/——ResearchAndMarkets.com的产品中增加了“全球中性粒细胞减少症市场（2023-2028）竞争分析，新型冠状病毒肺炎的影响，安索夫分析”报告。

The Global Neutropenia Market estimated at USD 4.34 Bn in 2023, is expected to reach USD 5.86 Bn by 2028 growing at a CAGR of 6.21%.

2023年全球中性粒细胞减少症市场估计为43.4亿美元，预计到2028年将达到58.6亿美元，复合年增长率为6.21%。

Neutropenia is a medical disorder characterized by an unusually low quantity of neutrophils, a type of white blood cell that plays an important part in the immunological response of the body. It can weaken the immune system, making people more vulnerable to infections, and it can be caused by a variety of factors, including particular drugs or medical conditions..

中性粒细胞减少症是一种医学疾病，其特征是中性粒细胞数量异常少，中性粒细胞是一种白细胞，在人体的免疫反应中起着重要作用。它可以削弱免疫系统，使人们更容易受到感染，并且可能由多种因素引起，包括特定的药物或医疗条件。。

The rising prevalence of leukemia, a kind of blood cancer frequently associated with neutropenia, is a major market driver for neutropenia. As the number of leukemia patients increases, so does the demand for treatments that target low neutrophil numbers. This tendency has generated an emphasis on developing medicines that increase neutrophil production, hence improving patient outcomes and quality of life..

白血病（一种经常与中性粒细胞减少症相关的血癌）患病率的上升是中性粒细胞减少症的主要市场驱动因素。随着白血病患者数量的增加，针对低中性粒细胞数量的治疗需求也在增加。这种趋势引起了人们对开发增加中性粒细胞产生的药物的重视，从而改善了患者的预后和生活质量。。

Increased research and development initiatives have resulted from a better understanding of neutropenia's influence on patients. To fight neutropenia more effectively, pharmaceutical companies are investing in new drug research and treatment options. The launch of new medications with enhanced efficacy and safety profiles improves the market outlook overall..

对中性粒细胞减少症对患者的影响有了更好的了解，从而增加了研究和开发计划。为了更有效地对抗中性粒细胞减少症，制药公司正在投资新药研究和治疗选择。具有增强功效和安全性的新药的推出改善了整体市场前景。。

The market for cancer supportive treatments, especially those for neutropenia management, has seen a trend away from more expensive branded medications and towards less priced biosimilars. This transformation is being driven by cost-effectiveness and increasing access to high-quality treatment choices, which will broaden the reach of the neutropenia market and benefit patients worldwide..

支持癌症治疗的市场，尤其是中性粒细胞减少症治疗的市场，已经出现了从更昂贵的品牌药物转向价格更低的生物仿制药的趋势。这种转变是由成本效益和获得高质量治疗选择的机会增加所驱动的，这将扩大中性粒细胞减少症市场的覆盖面，并使全世界的患者受益。。

The emergence of a strong pharmacological pipeline primarily addressing neutropenia treatment creates a market potential. With multiple promising medications in various phases of research, this signifies a substantial advancement in neutropenia management. When these pharmaceuticals hit the market, they will be able to address unmet medical needs, attract investment, and enhance patient outcomes..

主要针对中性粒细胞减少症治疗的强大药理学管道的出现创造了市场潜力。在各个研究阶段使用多种有前途的药物，这意味着中性粒细胞减少症管理取得了实质性进展。当这些药物进入市场时，它们将能够满足未满足的医疗需求，吸引投资，并提高患者的治疗效果。。

However, the market for neutropenia is restricted by high treatment costs. The costs of treating neutropenia, including drugs and supportive care, can be prohibitively expensive for individuals and healthcare systems, limiting access and uptake of these therapies.

然而，中性粒细胞减少症的市场受到高治疗成本的限制。治疗中性粒细胞减少症（包括药物和支持治疗）的费用对于个人和医疗保健系统来说可能会非常昂贵，从而限制了这些疗法的使用和吸收。

The neutropenia market faces the challenge of managing tight laws and regulations for product approvals. Long and complicated approval processes imposed by regulatory bodies can cause delays in drug development and market access, providing challenges for pharmaceutical companies wanting to deliver new neutropenia therapies..

中性粒细胞减少症市场面临着管理严格的产品批准法律法规的挑战。监管机构实施的漫长而复杂的审批流程可能会导致药物开发和市场准入的延误，为希望提供新的中性粒细胞减少症疗法的制药公司带来挑战。。

Market Segmentation:

市场细分：

The Global Neutropenia Market is segmented based on Treatment, Distribution Channel, and Geography.

全球中性粒细胞减少症市场根据治疗，分销渠道和地理位置进行细分。

By Treatment, the Global Neutropenia Market is classified into Colony-Stimulating Factors (CSFs), Antibiotics, and Antivirals.

通过治疗，全球中性粒细胞减少症市场分为集落刺激因子（CSF），抗生素和抗病毒药物。

Colony-Stimulating Factors (CSFs) hold a larger market share. CSFs are especially designed to increase white blood cell production, so addressing the underlying cause of neutropenia, making them a primary and more targeted therapy option for treating this illness.

集落刺激因子（CSF）占有较大的市场份额。CSF特别旨在增加白细胞的产生，从而解决中性粒细胞减少的根本原因，使其成为治疗这种疾病的主要和更有针对性的治疗选择。

By Distribution Channel, the Global Neutropenia Market is classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

根据分销渠道，全球中性粒细胞减少症市场分为医院药房，零售药房和在线药房。

Hospital Pharmacies hold a significant market share. Due to the specialized nature of these treatments and the necessity for close monitoring, healthcare facilities play an important role in dispensing and managing neutropenia drugs.

医院药房占有很大的市场份额。由于这些治疗的特殊性和密切监测的必要性，医疗机构在分配和管理中性粒细胞减少症药物方面发挥着重要作用。

By Geography, the Global Neutropenia Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.

根据地理位置，全球中性粒细胞减少症市场分为美洲，欧洲，中东和非洲以及亚太地区。

The Americas hold a larger market share. This was due to parameters such as the region's increased prevalence of neutropenia-related illnesses, improved healthcare infrastructure, and greater availability to advanced medical treatments.

美洲拥有较大的市场份额。这是由于该地区中性粒细胞减少症相关疾病患病率增加，医疗基础设施改善以及先进医疗的可用性提高等因素。

Company Profiles

公司简介

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are BeyondSpring Pharmaceuticals, Coherus Biosciences, Myelo Therapeutics, Spectrum Pharmaceuticals, etc..

该报告详细分析了市场上的竞争对手。它涵盖了市场上上市公司的财务业绩分析。该报告还提供了有关公司近期发展和竞争情景的详细信息。本报告涵盖的一些公司是BeyondSpring Pharmaceuticals，Coherus Biosciences，Myelo Therapeutics，Spectrum Pharmaceuticals等。。

Competitive Quadrant

竞争象限

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc..

该报告包括竞争象限，这是一种专有工具，用于根据公司的行业地位得分和市场绩效得分来分析和评估公司的地位。该工具使用各种因素将玩家分为四类。分析中考虑的一些因素包括过去3年的财务业绩、增长战略、创新得分、新产品发布、投资、市场份额增长等。。

Report Highlights:

报告亮点：

A complete analysis of the market, including the parent industry

对市场（包括母行业）的全面分析

Important market dynamics and trends

重要的市场动态和趋势

Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.

影响分析-应对风险并做出战略和运营决策以应对市场环境变化的综合评估。

Market segmentation

市场细分

Competitive Analysis: Comparative analysis of competitor

竞争分析：竞争对手的比较分析

Historical, current, and projected size of the market based on value and volume

基于价值和数量的历史、当前和预测市场规模

Market size of the US states

美国各州的市场规模

Market shares and strategies of key players

主要参与者的市场份额和策略

Recommendations to companies for strengthening their foothold in the market.

建议公司加强其在市场中的立足点。

Company Coverage:

公司范围：

Amgen

安进

Baxter International Inc.

巴克斯特国际公司。

BeyondSpring Pharmaceuticals

BeyondSpring制药公司

Biogen Inc.

Biogen股份有限公司。

Cantargia

Cantargia

Coherus Biosciences

Cohereus生物科学

Dong-A ST

东阿街

Enzychem Lifesciences

Enzychem生命科学

Gilead Sciences, Inc.

吉利德科学公司。

Kyowa Kirin

输入

Merck & Co., Inc.

默克公司股份有限公司。

Myelo Therapeutics

骨髓治疗学

Mylan Institutional (Fulphila)

迈兰机构（富尔菲拉）

Novartis Pharmaceuticals

诺华制药公司

Partner Therapeutics

合作伙伴治疗学

Pfizer

辉瑞公司

Sandoz (Novartis)

Sandoz（诺华）

Sanofi S.A.

赛诺菲美国。

Spectrum Pharmaceuticals

光谱制药公司

Teva Pharmaceutical

瓦制药

For more information about this report visit https://www.researchandmarkets.com/r/o2lqb1

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/o2lqb1

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

关于ResearchAndMarkets.com ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。

Media Contact: Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

媒体联系人：研究与市场高级Slaura WoodManagerpress@researchandmarkets.com对于E.S.T办公时间，请拨打+1-917-300-0470（对于美国）/CAN免费电话+1-800-526-8630（对于GMT办公时间），请拨打+353-1-416-8900（对于美国）。S、 传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

徽标：https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

来源研究和市场